Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Akamai Technologies, Inc. (AKAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Akamai Technologies, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.78 (market cap $5.07B), while Akamai Technologies, Inc. trades at $123.75 (market cap $16.77B). The key difference: Akamai Technologies, Inc. is far larger — about 3.3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Akamai Technologies, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | AKAM | |
|---|---|---|
Market Cap | $5.07B | $16.77B |
Sector | Health | Technology |
52-Week High | $29.41 | $161.14 |
52-Week Low | $20.06 | $71.97 |
Enterprise Value | $4.19B | $22.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Akamai Technologies (AKAM) trades at $117.65, up 6.43% on the day, buoyed by a recent analyst upgrade. The stock shows bearish technical signals but has beaten earnings estimates for three consecutive quarters, with Q2 2026 revenue growth of 5% year-over-year. Profit margins are under pressure due to increased infrastructure investments, though cloud and security demand remains strong.
The outlook is mixed: solid revenue growth and a consensus price target of $150.11 suggest upside, but margin compression and bearish technicals pose risks. Investors should weigh the company's strategic positioning in AI and cybersecurity against profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →
